Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388120 | 0.86 | CHRNB2 (0.39) | RETHTR2AACP3IDO1CYP11B2 | |
| SCHEMBL6385748 | 0.86 | ALOX12 (0.42) | RETHTR2APRCPGAA | |
| SCHEMBL6385756 | 0.84 | CYP2D6 (0.40) | RETHTR2AACP3CYP11B2 | |
| SCHEMBL4703520 | 0.80 | ACP3 (0.44) | RETHTR2AACP3HTR6IDO1 | |
| SCHEMBL6388137 | 0.78 | ALDH1A1 (0.47) | HTR2AHTR6GAA | |
| SCHEMBL30578367 | 0.77 | IDO1 (0.42) | HTR6IDO1PDPK1CYP11B2 | |
| SCHEMBL1922245 | 0.77 | IDO1 (0.42) | HTR6IDO1PDPK1CYP11B2 | |
| SCHEMBL2541173 | 0.77 | IDO1 (0.42) | HTR6IDO1PDPK1CYP11B2 | |
| SCHEMBL4698772 | 0.77 | GPR3 (0.37) | HTR2A | |
| SCHEMBL3541909 | 0.74 | IDO1 (0.45) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| WO-2022149610-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | ペプチドリーム株式会社 | 2022-07-14 | — | — | WO | disclosed |
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | RET 1869/4885HTR2A 282/4885ACP3 3513/4885 |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | GMPS, MAPT, UROD | RET 1037/4885HTR2A 2165/4885ACP3 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.